SCHEMBL7050282

SCHEMBL7050282

O=C(O)C(CC1CCCCC1)CP(=O)(O)CSc1cccc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 2/20 0.49
MMP1 P03956 5/20 0.40
MMP13 P45452 2/20 0.40
METAP2 P50579 2/20 0.39
METAP1 P53582 2/20 0.39
CNR1 P21554 4/20 0.35
CNR2 P34972 3/20 0.35
DPEP1 P16444 1/20 0.35
ANPEP P15144 2/20 0.35
ERAP2 Q6P179 2/20 0.35
ATM Q13315 1/20 0.35
HPGD P15428 2/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7046958 0.83 MMP1 (0.44) ACP3MMP1MMP13DPEP1ANPEP
SCHEMBL7052614 0.82 METAP2 (0.41) ACP3MMP1MMP13METAP2METAP1
SCHEMBL7049049 0.80 ERAP2 (0.46) ACP3ANPEPERAP2
SCHEMBL7047072 0.80 RXFP1 (0.44) ACP3MMP1MMP13MEN1ALDH1A1
SCHEMBL7051270 0.79 MEN1 (0.39) MMP1ANPEPERAP2HPGDMEN1
SCHEMBL7050257 0.79 MEN1 (0.38) MMP1HPGDMEN1ALDH1A1LMNA
SCHEMBL7047064 0.78 ERAP1 (0.43) ANPEPERAP2
SCHEMBL7052118 0.77 GRIK1 (0.43) ANPEPERAP2
SCHEMBL7054019 0.76 ACP3 (0.43) ACP3METAP2METAP1ATMHPGD
SCHEMBL5053043 0.75 MMP1 (0.61) MMP1MMP13ANPEPERAP2ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 ACP3 708/4885MMP1 2/4885MMP13 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.